Merck Moves to Exclude Causation Testimony Ahead of First Federal Vioxx Trial

NEW ORLEANS - Merck & Co. has filed a motion in the first federal Vioxx case slated to go to trial this month, seeking to exclude causation evidence presented by several of the experts designated to testify on behalf of the plaintiff. In re: Vioxx Products Liability Litigation, No. 05-4046 (E.D. La.).

The Oct. 21 motion filed in the U.S. District Court for the Eastern District of Louisiana contends that plaintiff's experts have failed to present evidence sufficient to prove that the 25 mg of Vioxx that plaintiff Richard Irvin took daily for less than one month was the cause …